Animal Models Core

动物模型核心

• 批准号: 8465815
• 负责人: Richard Arnold Bowen
• 金额: $ 26.15万
• 依托单位: COLORADO STATE UNIVERSITY
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至 2015-04-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8465815
• 关键词: Aerosols; Animal Disease Models; Animal Experiments; Animal Model; Animals; Antibiotic Therapy; Area; Autopsy; Biological Assay; Blood specimen; Budgets; Canis familiaris; Clinical; Clinical Chemistry; Clinical Trials; Clinical Trials Design; Collection; Complex; Containment; Data; Data Analyses; Development; Diagnostic; Diagnostic tests; Disease; Domestic Animals; Dose; Emerging Communicable Diseases; Evaluation; Exposure to; Family suidae; Fee Schedules; Fee-for-Service Plans; Funding; Goals; Goat; Government; Hematology; Human; Human Resources; Immune response; Immunologics; Income; Institution; Intervention; Lung; Mission; Modeling; Monitor; Morbidity - disease rate; Mus; National Institute of Allergy and Infectious Disease; Non-Rodent Model; Organ; Pathogenesis; Pathologic; Performance; Pharmaceutical Preparations; Phase I Clinical Trials; Positioning Attribute; Preparation; Reagent; Research; Research Personnel; Resources; Rodent Model; Route; Sampling; Serum; Services; Testing; Therapeutic; Therapeutic Agents; Therapy Clinical Trials; Time; Training; United States National Institutes of Health; Vaccine Adjuvant; Vaccines; Viral; Work; Writing; animal rule; antimicrobial drug; base; biodefense; design; good laboratory practice; immunoregulation; mortality; pathogen; product development; programs; research clinical testing; research study; response; tool; vaccine efficacy

The primary mission of the Animal Models Core (Core C) is to conduct animal challenge trials in support of studies by investigators within the RMRCE, at other RCEs and with other governmental, private and academic institutions. These services will be tailored to the needs of the investigator and program, ranging from simple morbidity and mortality experiments, to more complex studies involving aerosol challenges, intense clinical evaluation (i.e. blood sampling over time, telemetric monitoring, hematology), necropsy, histopathologic evaluation and organ pathogen loads. The work will be fee-for-service to investigators, with different fee schedules for RCE and US government investigators versus those from non-RCE academic institutions and commercial entities. In addition to this primary focus on service, Core C personnel will: 1) Assist investigators in the design of appropriate animal experiments, including writing the animal use, select agent and animal budget portions of proposals. This is viewed as a valuable and important service which will ultimately augment program income and contribute to the biodefense effort. 2) Establish new, and enhance existing, rodent models in response to or anticipation of investigator needs. One goal for Year 1 will be to establish, for selected bacterial pathogens, the maximum interval postchallenge at which initiation of high-dose (relevant) antibiotic therapy will allow survival; these data will provide reference points to assist in designing and conducting trials to evaluate therapeutic agents to be applied post-exposure. Another example of enhancing current models will be to characterize the hematologic and clinical chemistry alterations associated with disease pathogenesis; again, this will be valuable in evaluating efficacy of pharmacologic or immunologic interventions. 3) Promote the use of non-rodent models for certain pathogens. Such models could provide large quantities of serum and other samples as reference reagents and to test diagnostic platforms, to provide natural host bases for vaccine and therapeutic trials, and to allow realistic ICU-type monitoring in trials designed to evaluate therapies for human use. Core C is uniquely positioned among RCEs to provide such capabilities. Core C will support all three of the RMRCE Integrated Research Foci on Immunomodulation, Adjuvants and Vaccines (IRF 1), Bacterial Therapeutics (IRF 2), and Viral Therapeutics (IRF 3). Its resources will be utilized by RPs 1.5, 1.6, 1.7, 1.8, 2.3, 2.6, 2.7, 3.3, 3.5 and 3.6.

动物模型核心（核心 C）的主要任务是进行动物挑战试验以支持 RMRCE、其他 RCE 以及其他政府、私人和机构的研究人员进行的研究 学术机构。这些服务将根据研究者和项目的需求量身定制，范围包括 从简单的发病率和死亡率实验，到涉及气溶胶挑战的更复杂的研究， 密集的临床评估（即随着时间的推移进行血液采样、遥测监测、血液学）、尸检、 组织病理学评估和器官病原体负荷。这项工作将向调查人员收取服务费用， RCE 和美国政府调查人员与非 RCE 学者的费用表不同 机构和商业实体。除了主要关注服务之外，核心 C 人员还将： 1) 协助研究者设计适当的动物实验，包括撰写动物用途、 选择提案的代理人和动物预算部分。这被视为一项有价值且重要的服务 这最终将增加计划收入并为生物防御工作做出贡献。 2) 建立新的并增强现有的啮齿动物模型，以响应或预测研究者的需求。 第一年的一个目标是为选定的细菌病原体确定攻击后的最大间隔 此时开始高剂量（相关）抗生素治疗将允许生存；这些数据将 提供参考点以协助设计和进行试验以评估治疗药物 应用曝光后。增强当前模型的另一个例子是表征 与疾病发病机制相关的血液学和临床化学变化；再次，这将是 对于评估药物或免疫干预的功效很有价值。 3) 推广使用非啮齿动物模型来研究某些病原体。此类型号可以提供大量 血清和其他样品作为参考试剂和测试诊断平台，提供天然宿主 疫苗和治疗试验的基础，并允许在试验中进行真实的 ICU 型监测，旨在 评估人类使用的疗法。 Core C 在提供此类功能的 RCE 中具有独特的地位。 核心 C 将支持所有三个 RMRCE 综合研究重点：免疫调节、佐剂和 疫苗 (IRF 1)、细菌治疗 (IRF 2) 和病毒治疗 (IRF 3)。其资源将是 由 RP 1.5、1.6、1.7、1.8、2.3、2.6、2.7、3.3、3.5 和 3.6 使用。